Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

The early clinical success and subsequent US Food and Drug Administration approval of chimeric antigen receptor (CAR)-T cell therapy for leukemia and lymphoma affirm that engineered T cells can be a powerful treatment for hematologic malignancies. Yet this success has not been replicated in solid tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Neeser, A., Ramasubramanian, R., Wang, C., Ma, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362352/
https://www.ncbi.nlm.nih.gov/pubmed/37483659
http://dx.doi.org/10.1016/j.iotech.2023.100385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362352/
https://www.ncbi.nlm.nih.gov/pubmed/37483659
http://dx.doi.org/10.1016/j.iotech.2023.100385

Ejemplares similares